Charcoal and Charcoal-based Toothpastes
Charcoal and charcoal-containing products, such as toothpastes, are popular among the public. Nevertheless, its safety and efficacy has not yet been proven and the long-term effects are not completely known.

CHARCOAL AND ITS USE IN COSMETICS

Charcoal and charcoal-based toothpastes and products for teeth are becoming more and more popular. It is easy to find toothpastes containing charcoal in drug stores, pharmacies and online websites.

Charcoal is the dried, carbonaceous material obtained from the heating of organic substances. In cosmetics and personal care products, charcoal is used as an abrasive, absorbent, deodorant and opacifying agent. Besides cosmetic products, these ingredients are also used in other areas (e.g., as a colourant in food).

The fine black powder obtained by burning animal bones in a closed container (charcoal, bone) is used as a colourant in cosmetic products and it consists primarily of a mixture of carbon, calcium phosphate and calcium carbonate. It is included in Annex IV (list of colourants allowed in cosmetic products) of the European Regulation (EC) No 1223/2009 and when used to impart colour to cosmetics in the European Union, this ingredient is called CI 77267.

The type of charcoal that is usually used in tooth products is ‘activated charcoal’ and it consists in a fine grain powder made from wood, coconut shells and other natural substances that are oxidized under extreme heat.

The fine grain of charcoal contained in toothpaste works as a gentle/mild abrasive and may help to remove surface stains on teeth or absorb surface stains to some degree. It does not have any action in intrinsic stains, below the enamel. Activated charcoal might be too abrasive for a daily use, wearing down the enamel, exposing the dentine and resulting in tooth sensitivity. Toothpastes containing charcoal don’t usually contain fluoride, which is an important substance for teeth protection against cavities and decay. These products may also stain older teeth and its effects on dental restorations are not completely known.

Regarding the safety and effectiveness of tooth whitening products, the American Dental Association (ADA) states that whitening can only be achieved either by bleaching with peroxide or by using a polishing/chemical agent that removes surface stains. Moreover, according to ADA, there is no evidence showing that dental products with charcoal are safe or effective for teeth. A literature review published in the Journal of the American Dental Association (JADA) in 2017 reaffirmed and supported this conclusion. The results of the literature review showed insufficient clinical and laboratory data to substantiate the safety and efficacy claims of charcoal and charcoal-based dentifrices. Studies, at larger-scale and better designed, are needed to establish conclusive evidence. It is advised for patients to be cautious when using these products.

In sum, charcoal dentifrices may help in surface stains, but their efficacy and safety are yet to be demonstrated. Caution should be taken in using this type of products.

If you have any doubts or wish to get more information about toothpaste formulation and its ingredients’ safety profile, do not hesitate to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Charcoal and charcoal-based dentifrices – A literature review. 2017. The Journal of the American Dental Association (JADA). Available at: https://jada.ada.org/article/S0002-8177(17)30412-9/abstract#%20
  3. Charcoal Toothpaste for Teeth Whitening: The Pros and Cons. Healthline. Available at: https://www.healthline.com/health/dental-and-oral-health/charcoal-toothpaste

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »